Fresenius Medical Care AG (FMS)
| Market Cap | 11.78B -15.3% |
| Revenue (ttm) | 22.12B -0.8% |
| Net Income | 934.32M +14.6% |
| EPS | 1.68 +23.5% |
| Shares Out | 259.51M |
| PE Ratio | 13.52 |
| Forward PE | 10.11 |
| Dividend | $0.61 (2.67%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 1,396,144 |
| Open | 23.00 |
| Previous Close | 22.95 |
| Day's Range | 22.53 - 23.00 |
| 52-Week Range | 20.02 - 26.42 |
| Beta | 0.79 |
| Analysts | Hold |
| Price Target | 22.40 (-1.5%) |
| Earnings Date | Nov 3, 2026 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for FMS stock is "Hold." The 12-month stock price target is $22.4, which is a decrease of -1.50% from the latest price.
News
Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition
Washington state filed an antitrust lawsuit on Tuesday accusing DaVita and Germany's Fresenius Medical Care , the largest kidney dialysis providers in the US, of suppressing competition for kidney spe...
Fresenius Medical Care AG Places Bond with a Volume of 500 million Euros
Fresenius Medical Care AG announced that it has successfully placed a bond with a volume of €500 million. The bond is scheduled to mature in February 2032 and carries a coupon of 4.250% p.a. It was is...
Fresenius Medical downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Fresenius Medical (FMS) to Underweight from Equal Weight with a price target of EUR 35, down from EUR 44.50. The firm cites its “increasing concerns” over the company’s…
GOLDMAN SACHS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral'
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Fresenius Medical Care (FMC) von 38 auf 37,50 Euro gesenkt und die Einstufung auf "Neutral" belassen. Analyst ...
What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures and inflation weighed on results, while the co...
What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call
Hospital Stocks - Best Hospital Stocks to BuyFresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported broadly stable third-quarter revenue and a decline in operating income as reimbursement pressures ...
Fresenius raises 2026 outlook for second time after strong Q3
Healthcare group Fresenius lifted its full-year expectations on Wednesday after reporting higher-than-anticipated third-quarter results, as strong performance at the Kabi and Helios divisions suppor...
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care AG Reports Q3 2026 Results and Narrows Full Year Outlook
Fresenius Medical Care AG reported its third quarter 2026 financial results, highlighting a 1% increase in revenue to EUR 4,937 million compared to the prior year, though revenue declined by 1% at con...
Fresenius Medical Care AG Earnings Call Transcript: Q3 2026
Q3 revenue was broadly stable, while adjusted operating income declined 6% at constant currency amid TDAPA and inflation pressures. FY2026 operating income guidance moved to flat-to-negative mid-single digits; a EUR 300m–EUR 350m headwind is expected in 2027.
Fresenius Medical Care AG Slides: Q3 2026
Fresenius Medical Care AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Fresenius Medical Care AG Earnings release: Q3 2026
Fresenius Medical Care AG released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Fresenius Medical Care AG Quarterly report: Q3 2026
Fresenius Medical Care AG has published its Q3 2026 quarterly earnings report on November 3, 2026.
Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook
Stable organic revenue1 development driven by growth in Care Delivery and Care Enablement, offset by the expected decline in profit-neutral Value-Based Care Operating income2 decreased by 6%, due to r...
Fresenius Medical Q3 Profit Falls; Revises FY26 Operating Income Outlook, Backs Revenue View
(RTTNews) - Fresenius Medical Care AG (FME.DE, FMS), a provider of kidney care products and services, on Tuesday reported lower profit for the third quarter of fiscal 2026, while revenue edged up from...
Fresenius Medical Care AG Q3 Profit Declines
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius Medical Care AG (FME.DE) released earnings for third quarter that Drops, from last yearThe company's bottom line totaled EUR160 million, or EUR0.61 ...
Fresenius Medical cuts top end of 2026 profit outlook
German dialysis specialist Fresenius Medical Care cut the upper end of its 2026 operating income outlook on Tuesday after US treatment volumes declined for a third consecutive quarter, as regulatory...
Fresenius Medical Care Breaks Above 200-Day Moving Average - Bullish for FMS
In trading on Thursday, shares of Fresenius Medical Care (Symbol: FMS) crossed above their 200 day moving average of $22.87, changing hands as high as $23.11 per share. Fresenius Medical Care shares a...
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions exp...
Investors unlikely to find positive Fresenius take from HHS plan, says JPMorgan
After HHS published a new Kidney Care National Plan, JPMorgan said bears will focus on the strong rhetoric around the large incumbent providers, Fresenius Medical (FMS) and DaVita (DVA), and…
EQS-DD: Fresenius Medical Care AG: Martin Fischer, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2023)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.10.2026 / 17:16 CET/CEST The issuer is solely responsi...
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and eviden...
Fresenius Medical price target lowered to $24 from $25 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $24 from $25 and keeps a Hold rating on the shares as part of broader research now previewing Q3…
Fresenius Medical Care Names Shervin Korangy CEO
(RTTNews) - Fresenius Medical Care AG (FME.DE, FME) announced that Shervin J. Korangy will become Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. He will s...